Nine cancer centers share $8.9 million grant to improve treatment for neuroblastoma, a cancer that strikes children

June 11, 2000

With an $8.9 million grant from the National Cancer Institute, nine institutions have joined forces to develop and test new treatments for neuroblastoma, an aggressive cancer that only strikes children. The principal investigator of the NCI project program grant to develop those new therapies is Robert C. Seeger, MD, of Childrens Hospital Los Angeles and the University of Southern California. UCSF pediatric oncologist Katherine K. Matthay, MD, is principal investigator of the clinical consortium, New Approaches to Neuroblastoma Therapy (NANT), which aims to bring to the bedside the most promising strategies to improve the outcome of children with this disease.

Neuroblastoma is the most common cancer among infants and the second most common solid tumor malignancy in children under five. At the time they are diagnosed, 45 percent of affected children have high-risk disease, with the cancer often spreading throughout the body. A nationwide Phase III clinical trial led by Matthay, who is director of pediatric clinical oncology at the Children's Medical Center at UCSF, last year showed a three-fold improvement in disease-free survival from high-risk neuroblastoma due to a new combination of therapies. But even with this improvement, only 40 percent of children with the most dangerous form of neuroblastoma survive for five years without a recurrence.

"In spite of the best therapies we have available, neuroblastoma recurs in many children affected by it, and those children have a poor prognosis," said Matthay. "That is why we formed this new consortium."

Seeger, who is professor of hematology/oncology and deputy director of research at Childrens Hospital Los Angeles and the Department of Pediatrics at the Keck School of Medicine at the University of Southern California, said that the NCI project program grant will allow investigators at the nine institutions to share research information and potentially speed the development of strategies that will enhance the effectiveness of current therapies.

"Our goal is to improve disease-free survival for 90 percent or more of children with neuroblastoma," Seeger said.

Four different laboratory-based projects will investigate the promise of different strategies to stop tumors and their metastases, by targeting drugs to neuroblastoma tumors and by enhancing the drugs' effectiveness at killing even those cancer cells that are resistant to other drugs. Those projects will be led by investigators at Childrens Hospital Los Angeles (CHLA), the Indiana University and the University of Southern California.

The fifth major project of the study, led by Matthay, will translate the most promising of these strategies into small-scale Phase I - II clinical trials, offered to children in the context of the best current treatment for their stage of neuroblastoma. If these steps show that a strategy can be delivered safely, and show evidence that it will be effective, the method will be offered to the nationwide NCI-sponsored children's cancer research networks for large-scale Phase III clinical trials.

Such large-scale nationwide trials, with many institutions working together, are credited with major advances against childhood cancer in the past 25 years. Some children's cancers have high cure rates, and treatments for others have improved. Seeger, Matthay and their colleagues expect that the NANT project will speed the process of offering treatments for this particularly recalcitrant form of cancer -- and may be applicable to other childhood and adult malignancies as well.
-end-
The nine NANT institutions are: Childrens Hospital Los Angeles/USC; the Children's Medical Center/UCSF; Lucile Packard Children's Hospital/Stanford University; the University of Wisconsin; the University of Michigan; Cincinnati Children's Hospital; the University of Minnesota; the Indiana University, and Children's Hospital of Philadelphia/University of Pennsylvania.

The Children's Medical Center at UCSF has been providing specialized care to children since 1913. Children come to UCSF from throughout the western United States and around the world for expert treatment of cancer; heart defects, other congenital anomalies and other major diseases.

Reporter's Note: Matthay is on sabbatical but may be reached by phone or e-mail: For details contact Janet Basu at 415-476-2557 or jbasu@pubaff.ucsf.edu

Seeger will be available via a satellite press conference on July 13 from 8:30 to 10 a.m. For details contact Steve Rutledge at CHLA, 323-669-4121 srutledge@chla.usc.edu

For more information on clinical trials for neuroblastoma at UCSF, consult http://www.ucsf.edu/pressrel/1999/10/101302.html and http://cc.ucsf.edu/trials/peds_neuroblastoma_toc.html

For more information about NANT consult http://www.nant.org

For more information about children's cancer centers and clinical trials, consult the National Cancer Institute website at: http://rex.nci.nih.gov/massmedia/backgrounders/children.html

Katherine K. Matthay, MD -- background

Katherine K. Matthay, MD is UCSF professor in residence of pediatrics, chief of pediatric oncology and director of the pediatric oncology program at the Children's Medical Center at UCSF. Her work focuses on clinical research using cell-specific treatments, particularly in treatment of neuroblastoma.

She is chair of the Neuroblastoma Strategy Group in the Children's Cancer Group, a National Cancer Institute - directed organization of university and affiliate medical centers dedicated to clinical trials for the study and therapy of childhood cancer. She is principal investigator of a nine-university consortium, New Approaches to Neuroblastoma Therapy (NANT), which aims to bring to the bedside the most promising strategies to improve the outcome of children with this disease.

At UCSF, Matthay and her research group study treatments for children with progressive neuroblastoma, including the use of [131 I]-MIBG, targeted radiotherapy. She led the nationwide Children's Cancer Group Phase III clinical trials that in 1999 reported the success of autologous bone marrow transplantation plus 13-cis retinoic acid as adjuvant therapies with a three-fold improvement in disease free survival rates for children with high-risk neuroblastoma.

Matthay continues to participate in research on new methods of bone marrow transplant using purged marrow or peripheral blood stem cells. She participates in other innovative Phase I pilot studies for neuroblastoma treatment and in collaborative studies with basic research laboratories on the molecular genetics and immunology of neuroblastoma biology.

Matthay earned her degree in medicine from the University of Pennsylvania. She served as a fellow and postgraduate research fellow in pediatric hematology-oncology at UCSF and joined the UCSF faculty in 1980.

For more information consult http://cc.ucsf.edu/people/matthay_katherine.html

University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.